歡迎光臨源葉生物,登錄 | 注冊 |
當前位置: 首頁 > 小分子抑制劑 > Endocrinology/Hormones > Cilazapril Monohydrate

瀏覽歷史

S81104

Cilazapril Monohydrate

源葉(MedMol) 98%
  • 英文名:
  • Cilazapril Monohydrate
  • 別名:
  • CAS號:
  • 92077-78-6
  • 分子式:
  • C22H31N3O5.H2O
  • 分子量:
  • 435.51
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S81104-5mg 98% ¥600.00元 預計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S81104-10mg 98% ¥837.00元 預計交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S81104-50mg 98% ¥3348.00元 預計交期:2-3天 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻

質檢證書(COA)

摩爾濃度計算器

相關產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Cilazapril Monohydrate is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
  • 靶點: RAAS
  • 體內(nèi)研究:
    Cilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats.
  • 參考文獻:
    1. Nishida N, et al. Res Commun Chem Pathol Pharmacol, 1994, 84(2), 143-152. 2. Asahi T, et al. Thyroid, 2001, 11(11), 1009-1015. 3. Bhutto IA, et al. Life Sci, 1999, 64(3), PL27-39. 4. Sugimoto K, et al. J Pharmacol Sci, 2004, 94(1), 67-72. 5. Christe ME, et al. Am J Physiol, 1994, 267(5 Pt 2), H2050-2057.
  • 溶解性: Soluble  in  DMSO、Ethanol
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.296 ml 11.481 ml 22.962 ml
    5 mM 0.459 ml 2.296 ml 4.592 ml
    10 mM 0.23 ml 1.148 ml 2.296 ml
    50 mM 0.046 ml 0.23 ml 0.459 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Cilazapril Monohydrate is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.
  • 靶點: RAAS
  • 體內(nèi)研究:
    Cilazapril (1 mg/kg, daily) tends to decrease and the higher dose (10 mg/kg, daily) significantly decreases systolic blood pressure (SBP) in subtotal nephrectomized rats. Cilazapril attenuates the further development of protein uria in a dose-dependent manner in subtotal nephrectomized rats. Cilazapril attenuates the increase in plasma fibrinogen concentration and serum albumin concentration in a dose-dependent manner. Cilazapril reduces serum MCP-1 concentration in the nephrectomized rats. Cilazapril decreases hepatic fibrinogen synthesis through the alleviation of the local inflammatory process and the improvement of hypoalbuminemia. Cilazapril normalizes systolic arterial pressure to 121 mm Hg (SD) in the treated SHR-SP rats. Cilazapril decreases systolic arterial pressure to a nearly normal level and prevents hypertensive retinal vascular changes, probably by improving endothelial function. Cilazapril results in a marked decrease in the Kd of the renal arginine vasopressin (AVP) receptor and an increase in the plasma AVP level in the spontaneously hypertensive rat. Cilazapril exerts a rapid, complete, and persistent antihypertensive effect in the spontaneously hypertensive rats (SHR) in vivo but has no effect on SAP in the normotensive Sprague-Dawley rat. Cilazapril treatment depresses heart performance (28-35%) in SHR but has no effect in the Sprague-Dawley rats. Cilazapril decreases blood pressure to control values and reduces HW:BW in hyperthyroid rats.
  • 參考文獻:
    1. Nishida N, et al. Res Commun Chem Pathol Pharmacol, 1994, 84(2), 143-152. 2. Asahi T, et al. Thyroid, 2001, 11(11), 1009-1015. 3. Bhutto IA, et al. Life Sci, 1999, 64(3), PL27-39. 4. Sugimoto K, et al. J Pharmacol Sci, 2004, 94(1), 67-72. 5. Christe ME, et al. Am J Physiol, 1994, 267(5 Pt 2), H2050-2057.
  • 溶解性: Soluble  in  DMSO、Ethanol
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.296 ml 11.481 ml 22.962 ml
    5 mM 0.459 ml 2.296 ml 4.592 ml
    10 mM 0.23 ml 1.148 ml 2.296 ml
    50 mM 0.046 ml 0.23 ml 0.459 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系,公式為:


質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。
点击收缩